Send to

Choose Destination
See comment in PubMed Commons below
Clin Cancer Res. 2009 Mar 15;15(6):1845-7. doi: 10.1158/1078-0432.CCR-08-3087. Epub 2009 Mar 10.

HER-2, notch, and breast cancer stem cells: targeting an axis of evil.

Author information

  • 1University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA.


Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse, suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk